2025³â 04¿ù 22ÀÏ È­¿äÀÏ
 
 
  ÇöÀçÀ§Ä¡ > ´º½ºÁö´åÄÄ > Science & Technology

·£¼¶¿þ¾îºÎÅÍ µÅÁöµµ»ì±îÁö... ³ë·ÃÇØÁø »ç±âÇà°¢

 

Á¤Ä¡

 

°æÁ¦

 

»çȸ

 

»ýȰ

 

¹®È­

 

±¹Á¦

 

°úÇбâ¼ú

 

¿¬¿¹

 

½ºÆ÷Ã÷

 

ÀÚµ¿Â÷

 

ºÎµ¿»ê

 

°æ¿µ

 

¿µ¾÷

 

¹Ìµð¾î

 

½Å»óǰ

 

±³À°

 

ÇÐȸ

 

½Å°£

 

°øÁö»çÇ×

 

Ä®·³

 

Ä·ÆäÀÎ
Çѻ츲 ¡®¿ì¸®´Â ÇѽҸ²¡¯ ½Ò ¼Òºñ Ä·ÆäÀÎ ½Ã...
1000¸¸¿øÂ¥¸® Àΰø¿Í¿ì, °Ç°­º¸Çè Áö¿ø ¡®Æò...
- - - - - - -
 

Biocodex Strengthens Supply Chain Resilience with Kinaxis

The human microbiota pioneer invests in an agile and transparent supply chain to better meet patient needs
´º½ºÀÏÀÚ: 2024-12-28

OTTAWA, ONTARIO -- Biocodex, a pioneer and leader in human microbiota health, as well as an innovator in pharmaceuticals, has partnered with Kinaxis® Inc. (TSX: KXS), a global leader in end-to-end supply chain orchestration, to modernize and optimize its processes. Through this collaboration, Biocodex aims to achieve greater forecast accuracy, simplify the management of regulatory challenges, and enhance resilience against disruptions.

Biocodex is a French, family-owned, pharmaceutical company that has grown from microbiota pioneer to an international leader with its diverse portfolio focused on three areas of expertise: microbiota care, women’s health and orphan diseases. The pharmaceutical company serves patients in more than 100 countries with its three industrial facilities in France and Morocco, and R&D center also located in France.

“We are excited to work with Kinaxis and tap into their longstanding expertise in the life sciences sector and pharmaceutical industry,” said Cécile Jolivet, procurement & supply chain director at Biocodex. “Our main priority will always be to deliver medical innovation to patients. To continue doing that we are investing in our supply chain to make it as resilient as possible.”

As Biocodex continues to expand worldwide, the needs of its supply chain become more complex, heightening the need for complete end-to-end orchestration. The Kinaxis Maestro™ platform offers pharma-specific functionality and capabilities designed to combat challenges unique to the industry like expiry management, regulatory approvals and attribute-based planning.

“Patients seeking medical treatments show resiliency every day, so the supply chains helping to supply those treatments need to be just as resilient,” said Fabienne Cetre, executive vice president of EMEA at Kinaxis. “We’re thrilled to be working with Biocodex, ensuring they’ll be able to foresee and manage any disruption to their supply chain and that patients will have the medicine they need when they need it.”

With the addition of Biocodex to its growing customer base, Kinaxis continues to cement its footprint within the life sciences industry, which provides the brand-name and generic medicines that countless patients rely on. Managing supply chain complexities in biotechnology, cell and gene therapy, medical devices, over-the-counter medicines and more.



 Àüü´º½º¸ñ·ÏÀ¸·Î

Rigaku and SPERA PHARMA Initiate Strategic Partnership to Advanced Pharmaceutical Development
NETSCOUT Reports DDoS Attacks Targeting Critical Infrastructure Play a Dominant Role in Geopolitical Conflicts
Center for Disease Analysis Foundation Awards Third Round of Grants for the CDAF Relink Program
Motive and Telefónica Advance GSMA Open Gateway Initiative
Amazfit Announced the Bip 6 Smartwatch: The Everyday Smartwatch for Every Moment
SMART Modular Technologies Introduces its Non-Volatile CXL E3.S Memory Module
Tecnotree Recognized by Gartner as a Representative Vendor in 2025 Market Guide for CSP Revenue Management and Monetization Solutions

 

Dubai AI Week 2025 to Host World¡¯s Largest Generative AI Championship...
1GLOBAL: Message+ Technology for Financial Institutions Ensures Compli...
Telehouse Canada Announced Leadership Transition as It Enters Its Next...
Boyd Opens State of the Art Battery Material Test Lab to Safely Accele...
Tigo Energy Expands EI Residential with Smart Heating Integration at I...
Rockwell Automation and AWS Collaborate to Transform Manufacturing Thr...
Novotech Report Reveals Global Surge in Infectious Disease Trials as I...

 


°øÁö»çÇ×
¹Ìµð¾î¾Æ¿ì¾î Mediaour ØÚ体ä²们 ØÚô÷ä²Ùú MO ¿¥¿À ØÚä² ØÚä²
¾Ë¸®¿ìºê Alliuv ä¹备: ä¹联êó备, ¾Ë¶ã Althle ä¹÷åìÌ
¾Ë¸®¾Ë Allial Áß¹® Ç¥±â ä¹××尔 ä¹××ì³
´ºÆÛ½ºÆ® New1st Áß¹® Ç¥±â 纽ììãæ(¹øÃ¼ Òïììãæ), N1 纽1
¿£ÄÚ½º¸ð½º : À̾¾ 'EnCosmos : EC' Áß¹® Ç¥±â ì¤ñµ
¾ÆÀ̵ð¾î·Ð Idearon Áß¹® Ç¥±â ì¤îè论 ì¤îèÖå
¹ÙÀÌ¿ÀÀÌ´Ï Bioini Áß¹® Ç¥±â ù±药研 ù±å·æÚ
¿À½ºÇÁ·Ò Ausfrom 奥ÞÙÜØÙÌ, À£ÇÁ·Ò Welfrom 卫ÜØÙÌ
¿¡³ÊÇÁ·Ò Enerfrom 额ÒöÜØÙÌ ¿¡³ÊÀ¯ºñ Eneruv 额Òöêó备
º£³×ÇÁ·Ò º£³×ÀÎÅõ Áß¹® Ç¥±â 宝Ò¬ÜØÙÌ 宝Ò¬ì×öõ(ÜÄÒ¬ÜØÙÌ ÜÄ...
¾ËÇÁ·Ò Alfrom Áß¹® Ç¥±â ä¹尔ÜØÙÌ ä¹ì³ÜØÙÌ
´º½ºÁö ÇÑÀÚ Ç¥±â¿¡ ´ë¸¸½Ä À½Â÷ Ç¥±â '纽ÞÙó¢ ´Ï¿ì½ÃÁö' º´±â

 

ȸ»ç¼Ò°³ | ÀÎÀçä¿ë | ÀÌ¿ë¾à°ü | °³ÀÎÁ¤º¸Ãë±Þ¹æÄ§ | û¼Ò³âº¸È£Á¤Ã¥ | Ã¥ÀÓÇѰè¿Í ¹ýÀû°íÁö | À̸ÞÀÏÁÖ¼Ò¹«´Ü¼öÁý°ÅºÎ | °í°´¼¾ÅÍ

±â»çÁ¦º¸ À̸ÞÀÏ news@newsji.com, ÀüÈ­ 050 2222 0002, ÆÑ½º 050 2222 0111, ÁÖ¼Ò : ¼­¿ï ±¸·Î±¸ °¡¸¶»ê·Î 27±æ 60 1-37È£

ÀÎÅͳݴº½º¼­ºñ½º»ç¾÷µî·Ï : ¼­¿ï ÀÚ00447, µî·ÏÀÏÀÚ : 2013.12.23., ´º½º¹è¿­ ¹× û¼Ò³âº¸È£ÀÇ Ã¥ÀÓ : ´ëÇ¥ CEO

Copyright ¨Ï All rights reserved..